Highlights

  • Protagonist Therapeutics shares show triple-digit gains over one year despite recent monthly declines
  • EODHD/Others data indicates a current average analyst recommendation score of 1.77
  • The stock has traded between USD 33.70 and USD 96.54 over the past year

Protagonist Therapeutics (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing orally administered peptide-based therapies for immune-mediated and other serious diseases. The company applies its proprietary Peptide 2.0 platform to design molecules targeting G protein–coupled receptors and cytokine receptors, aiming to provide oral alternatives in areas traditionally dominated by injectable treatments. One of its lead candidates, PTG-100, is being developed for ulcerative colitis and Crohn’s disease, with the goal of limiting leukocyte migration to the gut.

Recent analyst commentary has contributed to continued attention on the stock. Jefferies Financial Group recently raised its price target, while maintaining its existing rating. Other brokerages have also revised their targets over recent months, with a mix of rating reaffirmations and upgrades. Based on EODHD/Others data, the current consensus target price is USD 100.54, representing a 21.06% difference relative to the prior close. This figure reflects aggregated analyst estimates rather than an expected outcome.

From a performance perspective, Protagonist Therapeutics shares have delivered varied results across different time horizons. According to EODHD/Others, the stock gained 119.71% over the past year and 87.56% over nine months. Over six months, the shares rose 54.28%, while the three-month period showed a gain of 9.35%. In contrast, one-month performance declined by 4.74%, with quarter-to-date and year-to-date figures both showing a decrease of 4.91%. The stock’s trading range highlights recent volatility. EODHD/Others data shows a 52-week high of USD 96.54, reached on December 15, 2025, and a 52-week low of USD 33.70, recorded on February 25, 2025. The last recorded price stood about 13.97% below the 52-week high.

In its most recent earnings release, Protagonist Therapeutics reported a quarterly loss per share that was slightly wider than consensus expectations, alongside revenue that came in below analyst estimates. The company continues to operate as a development-stage entity, with financial results closely tied to research progress and partnership activity rather than recurring commercial revenue.

Overall, current EODHD/Others data presents a picture of a stock that has delivered substantial longer-term gains, experienced near-term fluctuations, and remains closely watched due to analyst target revisions and clinical development milestones.